Asthma, because of its chronic nature, may adversely affect the life quality of patients leading to mental disturbances. Anxiety and depression can be accure more than on these patients compared with the healthy population. Life quality survey can be used to evaluate effect of asthma in the terms of physical, psychological and social function on the patients life. In particular, the importance of emotional factors come to the forefront more in the case which symptoms can not be controlled. Anxiety is the most common psychological disorders among patients who have respiratory system disease.
Materials and methods
We aimed to compare anxiety and depression levels of the patients with severe asthma before and after the omalizumab treatment. Patients’ anxiety levels were measured with state trait anxiety inventory (STAI) and depression levels were measured with beck depression scale.
Findings
Five male (%25), fifteen female (%25) patients enrolled in study. The average age of the patients were 50,25. The average score of beck depression scale of patients was 25,35 and 8,55 before and after treatment, relatively. The score was higher before treatment, it was statically meaningful when it compared with after treatment scores (p<0.001). The STAI average score was 52,05 before treatment and 42.95 after it. There was a statistically meaningful difference between the anxiety score average before and after the treatment (p<0.0001). The anxiety score was higher before the treatment.
Failure in symptom controlling in asthma can lead to depression. We think that these patients should be examined for psychological disorders. It may improve the quality of life.